Clinical trial
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
NCT00348790 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00348790 |
|---|---|
| Title | Vatalanib in Treating Patients With Recurrent or Progressive Meningioma |
| Official title | A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Sarcoma |
| Intervention type | Drug |
| Interventions | vatalanib |
| Enrollment | 25 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2010 |
| Completion | Jul 1, 2013 |
| First posted | Jul 6, 2006 |
| Last update posted | Oct 26, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: